Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)
NCT04340076Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab in plaque psoriasis, sponsored by Radboud University Medical Center. Started Aug 2020; status: completed.
02
Drugs
secukinumabixekizumabbrodalumabguselkumabrisankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04340076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340076.